FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

被引：0
|
作者：
Moore, K. N. [1 ]
Vergote, I. [2 ]
Oaknin, A. [3 ]
Colombo, N. [4 ]
Banerjee, S. [5 ]
Oza, A. M. [6 ]
Pautier, P. [7 ]
Kelly, C. M. [8 ]
Malek, K. [9 ]
Birrer, M. J. [10 ]
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Obstet & Gynecol, Oklahoma City, OK USA
[2] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[4] Ist Europeo Oncol, Dept Gynecol Oncol, Milan, Italy
[5] Royal Marsden, Gynaecol Unit, London, England
[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[7] Gustave Roussy Inst Cancerol, Med Oncol, Villejuif, France
[8] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland
[9] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[10] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
991TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    Gilbert, Lucy
    Oaknin, Ana
    Matulonis, Ursula A.
    Mantia-Smaldone, Gina M.
    Lim, Peter C.
    Castro, Cesar M.
    Provencher, Diane
    Memarzadeh, Sanaz
    Method, Michael
    Wang, Jiuzhou
    Moore, Kathleen N.
    O'Malley, David M.
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
  • [32] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Sabbatini, Paul
    Dupont, Jakob
    Aghajanian, Carol
    Derosa, Felicia
    Poynor, Elizabeth
    Anderson, Sybil
    Hensley, Martee
    Livingston, Phillip
    Lasonos, Alexia
    Spriggs, David
    McGuire, William
    Reinartz, Silke
    Schneider, Sally
    Grande, Cathy
    Lele, Shashikant
    Rodabaugh, Kerry
    Kepner, James
    Ferrone, Soldano
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5503 - 5510
  • [33] Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial
    Yuan, Guangwen
    Zhang, Keqiang
    Zheng, Hong
    Wu, Yan
    Sun, Haolin
    Zhang, Jiajing
    Sun, Xiyang
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 212 - 220
  • [34] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Herzog, Thomas J.
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Hays, John L.
    Monk, Bradley J.
    O'Malley, David M.
    Sehouli, Jalid
    Barlin, Joyce N.
    Graham, Julie R.
    Md, Monali Desai
    Wang, Yan
    Du, Yangchun
    Dalal, Rita P.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
    Moore, Kathleen N.
    Martin, Lainie P.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Kirby, Maurice William
    Zhou, Yinghui
    Michenzie, Mary F.
    Ponte, Joseph
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
    Matulonis, U. A.
    Moore, K. N.
    Martin, L. P.
    Vergote, I. B.
    Castro, C. M.
    Gilbert, L.
    Berkenblit, A.
    Birrer, M. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
  • [37] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Reply
    Sabbatini, Paul
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 4026 - 4027
  • [38] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [39] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Herzog, Thomas
    Moore, Kathleen
    Konstantinopoulos, Panagiotis
    Gilbert, Lucy
    Hays, John
    Monk, Bradley
    O'Malley, David
    Sehouli, Jalid
    Graham, Julie
    Desai, Monali
    Wang, Yan
    Du, Yangchun
    Sun, Lei
    Dalal, Rita
    Coleman, Robert
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S169 - S169
  • [40] Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
    Moore, Kathleen N.
    Chambers, Setsuko K.
    Hamilton, Erika P.
    Chen, Lee-May
    Oza, Amit M.
    Ghamande, Sharad A.
    Konecny, Gottfried E.
    Plaxe, Steven C.
    Spitz, Daniel L.
    Geenen, Jill J. J.
    Troso-Sandoval, Tiffany A.
    Cragun, Janiel M.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Lai, Zhongwu
    Chmielecki, Juliann
    Jones, Suzanne F.
    Spigel, David R.
    Cadoo, Karen A.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 36 - 44
12345